Cargando…

Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa?

Mycoplasma pneumonia e is a bacterium that lacks a cell wall. It produces infections all It produces infections worldwide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Varela, Ana Isabel Álvaro, Pérez, Aitziber Aguinaga, Ortega, Ana Navascués, Catalán, Jesús Castilla, Baquedano, Carmen Ezpeleta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238793/
https://www.ncbi.nlm.nih.gov/pubmed/36966384
http://dx.doi.org/10.37201/req/118.2022
_version_ 1785053356684738560
author Varela, Ana Isabel Álvaro
Pérez, Aitziber Aguinaga
Ortega, Ana Navascués
Catalán, Jesús Castilla
Baquedano, Carmen Ezpeleta
author_facet Varela, Ana Isabel Álvaro
Pérez, Aitziber Aguinaga
Ortega, Ana Navascués
Catalán, Jesús Castilla
Baquedano, Carmen Ezpeleta
author_sort Varela, Ana Isabel Álvaro
collection PubMed
description Mycoplasma pneumonia e is a bacterium that lacks a cell wall. It produces infections all It produces infections worldwide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique.
format Online
Article
Text
id pubmed-10238793
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-102387932023-06-04 Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? Varela, Ana Isabel Álvaro Pérez, Aitziber Aguinaga Ortega, Ana Navascués Catalán, Jesús Castilla Baquedano, Carmen Ezpeleta Rev Esp Quimioter Revisión Mycoplasma pneumonia e is a bacterium that lacks a cell wall. It produces infections all It produces infections worldwide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique. Sociedad Española de Quimioterapia 2023-03-27 2023 /pmc/articles/PMC10238793/ /pubmed/36966384 http://dx.doi.org/10.37201/req/118.2022 Text en © The Author 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Revisión
Varela, Ana Isabel Álvaro
Pérez, Aitziber Aguinaga
Ortega, Ana Navascués
Catalán, Jesús Castilla
Baquedano, Carmen Ezpeleta
Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa?
title Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa?
title_full Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa?
title_fullStr Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa?
title_full_unstemmed Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa?
title_short Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa?
title_sort mycoplasma pneumoniae y resistencias a macrólidos: ¿conocemos la situación en europa?
topic Revisión
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238793/
https://www.ncbi.nlm.nih.gov/pubmed/36966384
http://dx.doi.org/10.37201/req/118.2022
work_keys_str_mv AT varelaanaisabelalvaro mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa
AT perezaitziberaguinaga mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa
AT ortegaananavascues mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa
AT catalanjesuscastilla mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa
AT baquedanocarmenezpeleta mycoplasmapneumoniaeyresistenciasamacrolidosconocemoslasituacioneneuropa